Dr. Barry Bertolet presents a case series on the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs).
The series is based on cases where patient treatment included Aggrastat (tirofiban hydrochloride) injection and is intended to be an educational resource for fellows and those who may not be familiar with the use of GPIs.
These cases and testimonials are based on the experiences of a few people. Not all cases are identical. You are not likely to have similar results.
Important Safety Information about the use of Aggrastat is provided below.
Clinical studies performance with Aggrastat are provided in the full Prescribing Information.
Dr. Barry Bertolet is an interventional cardiologist out of the Cardiology Associates of North Mississippi in Tupelo, MS. He is currently the Governor-Elect of the Mississippi chapter of the American College of Cardiology (ACC). He is also the founding member of the Mississippi Health Care Alliance which is an organization that has developed the nation’s first statewide system for care for both heart attack and stroke. Here he presents three cases where he used Aggrastat in his practice:
A patient presents to the emergency department with dyspnea. Cardiac PET scan was performed which came back abnormal prompting a cardiac catheterization. During the procedure the patient developed an intracoronary clot. Watch to see what Dr. Bertolet did next.
A 56-year old female presents to the emergency department with acute respiratory distress and required intubation and mechanical ventilation. Her ECG was remarkable for inferior ischemia which prompted an urgent cardiac catheterization. Watch to see how Dr. Bertolet approached this case.
Aggrastat (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding.
Check out the experience of other healthcare providers in the US that use Aggrastat to reduce the rate of thrombotic complications for their patients during PCI.
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
or call 1-800-FDA-1088.